CAR T Cell Therapy Market – A Revolution in Cancer Treatment
Over the last few years, CAR T Cell therapy has gained wide recognition in the healthcare industry. CAR T cell is an innovative technique that involves removal of T Cells from patient’s blood before reinsertion using a genetically altered mechanism. The technology is still in the nascent stage; however, is expected to grow at double digit growth rate creating multi-billion absolute dollar opportunity for industry players in the near future. As of 2016, just over 40 companies are engaged in CAR T cell therapy market. Novartis International AG, Juno Therapeutics, and Kite Pharma Inc. are the only players that are expected to launch products by 2018. With long impending clinical trials and research activities carried out using chimeric antigen receptor cells (CAR-T) cells, these players in the pharmaceuticals industry are expected to launch various products in 2017 and commercialize them in the following two to three years.
The competition in the CAR T cell therapy market is projected to intensify following commercial launch of products of other companies by 2022. In 2015, Cellectis entered into clinical alliance with MD Anderson for development of UCARTCS1 in MM, UCART22 in ALL, UCART38 in T-cell ALL and UCART123 in a rare non-curable cancer.
The global CAR T cell therapy market is estimated to be valued at US$ 72.0 million in 2017 and is projected to expand exponentially at a CAGR of 46.1% during 2019 – 2028.
CD 19 to dominate the market throughout the forecast period
Acute lymphoblastic leukemia (ALL) is highly prevalent among children. Adults account for over 40% cases of ALL. Changing lifestyle along with increasing incidence of cancer among children necessitates an effective treatment approach in the healthcare industry for effective treatment of the same. As a result, CAR- T cell therapy has emerged as one of the potential therapies to address this issue. CD-19 marker is highly effective in tackling the growing incidence problem of ALL. The CD-19 antigen CAR T Cell segment is expected to be valued at US$ 1.2 billion by 2023 and is expected to continue dominate the market (in terms of revenue) through the remainder of the forecast period.
North America to retain its dominance in the CAR T cell therapy market through 2028
North America is home to state of the art R&D labs along and is characterized by high prevalence rate of blood cancer. Each year, over 171,000 people are diagnosed with blood cancer in the U.S. Of these, around 46% suffer from lymphoma (U.S. Leukemia & Lymphoma Society), thereby creating major market opportunity for CAR T cell therapy industry players to capitalize on highly lucrative growth opportunities in the region. North America is expected to account for 52.5% of overall market share by 2020. Kite Pharma Inc. along with Novartis International AG are expected to gain significant market share in the region, as these companies have already applied for U.S. Biologics License Application (BLA). Moreover, these companies have established dedicated manufacturing sites for CAR-T cell therapy products; Kite Pharma established its 43,500 square foot plant in the U.S. for production of CAR-T cell products. The plant is expected to produce up to 5,000 patient therapy products in 2018. In 2016, Juno Therapeutics invested US$ 20 million to set up of CAR-T cell products manufacturing facility in the U.S. These companies are analyzed to greatly benefit from first mover advantage.
Europe is expected to second-most prominent market (in terms of revenue) through 2023, post which it would lose it position to Asia Pacific. Asia Pacific market is expected to grow at the fastest rate, expanding at a CAGR of 62.5% between 2019 and 2028. Japan and China are the key regions in Asia Pacific that market players would focus on during the latter half of the forecast period to pave a way for higher return on investment (ROI).
Diversification of CAR T Cell in other therapeutics application is expected to create lucrative market opportunities for market players
Currently, Juno Therapeutics along with Kite Pharma and Novartis are working on CD 19 antigen—responsible for blood cancers. These companies also have a product roadmap to commercialize products based on CD 30 and 22 responsible for solid cancers. FDA approval of these products by 2025 is projected to drive the market growth over the latter half of the forecast period.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,#3200
Seattle, WA 98154